Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 24, 2015 2:31 PM ET


Company Overview of Miltenyi Biotec GmbH

Company Overview

Miltenyi Biotec GmbH develops and manufactures cell labeling reagents, cell separation and analysis devices, and systems for clinical applications globally. Its products include MACS sample preparation, MACS cell separation, MACS flow cytometry, MACS cell culture and stimulation, and MACS molecular; research areas include immunology, stem cell research, neuroscience, and cancer research; and clinical applications include clinical development, CliniMACS system, MACS GMP products, CryoMACS freezing products, TheraSorb, graft engineering, immunotherapy, tissue regeneration, and freezing products. The company was founded in 1989 and is based in Bergisch Gladbach, Germany with additional offices ...

Friedrich-Ebert-Straße 68

Bergisch Gladbach,  51429


Founded in 1989


49 2204 8306 0


49 2204 85197

Key Executives for Miltenyi Biotec GmbH

Chief Executive Officer
Global Head Clinical Products
General Manager of Gangnam District for Seoul
Compensation as of Fiscal Year 2014.

Miltenyi Biotec GmbH Key Developments

Miltenyi Biotec Opens New Office in South Korea; Appoints Daesuk Oh as General Manager of New Office

Miltenyi Biotec announced that it opened a new office in Seoul, Korea, enlarging the company's Asia-Pacific presence to six locations in five countries. Daesuk Oh has been appointed General Manager of the new office in the Gangnam district of Seoul.

Miltenyi Biotec Obtains License to Manufacture MB101 Antibody in Germany

The Arzneimittelüberwachungsbehörde of Mecklenburg-Vorpommern and the Paul-Ehrlich-Institut (PEI), the German medical regulatory authorities, have granted manufacturing license for therapeutic antibody MB101 to Miltenyi Biotec. The license allows the company to manufacture the humanized, monoclonal antibody under recombinant conditions in a mammalian cell line (CHO cells) in its GMP facility in Teterow, Germany. Vital MB101 project activities such as antibody engineering and humanization, cell line development, GMP-compliant manufacturing of drug substance and drug product, QC testing, antibody characterization, and stability studies were all accomplished at the facility.

Similar Private Companies By Industry

Company Name Region
Coley Pharmaceutical GmbH Europe
HUMAN Gesellschaft für Biochemica und Diagnostica mbH Europe
Novaliq GmbH Europe
Helmholtz Zentrum München, GmbH Europe
GenPharmTox BioTech AG Europe

Recent Private Companies Transactions

August 14, 2014
Lentigen Technology, Inc.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Miltenyi Biotec GmbH, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at